Marburg Virus News and Research

RSS

Marburg virus or simply Marburg is the common name for the the genus of viruses Marburgvirus, which contains one species, ''Lake Victoria marburgvirus''. The virus causes the disease Marburg Hemorrhagic Fever (MHF), also referred to as ''Marburg Virus Disease''.

Researchers Study how Marburg virus and host protein interaction help in developing inhibitors of virus

A protein that normally protects cells from environmental stresses has been shown to interact Marburg virus VP24, allowing the deadly Marburg virus to live longer and replicate better, according to a cell culture study led by scientists at the Icahn School of Medicine at Mount Sinai.

14 Mar 2014

Small-molecule drug effective in protecting nonhuman primates from lethal Marburg virus

For the first time, scientists have demonstrated the effectiveness of a small-molecule drug in protecting nonhuman primates from the lethal Marburg virus. Their work, published online in the journal Nature, is the result of a continuing collaboration between Army scientists and industry partners that also shows promise for treating a broad range of other viral diseases.

5 Mar 2014

Sarepta Therapeutics reports non-GAAP net loss of $29.1 million for Q4 2013

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today reported financial results for the three months and year ended December 31, 2013, and provided an update of recent corporate developments.

27 Feb 2014

Sarepta Therapeutics reports positive safety results from AVI-7288 Phase I study

Sarepta Therapeutics, Inc., a developer of innovative RNA-based therapeutics, today announced positive safety results from a Phase I multiple ascending dose study of AVI-7288 in healthy volunteers.

10 Feb 2014

BioCryst receives $2.5M to advance development of BCX4430 for Marburg virus disease treatment

BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has exercised an option to conduct the investigational new drug enabling program and to submit an IND.

30 Dec 2013

Biocryst Wins Potentially $22M NIAID Contract To Develop Marburg Virus Disease Drug

...

17 Sep 2013

TSRI scientists discover molecular mechanism by which deadly Ebola virus assembles

Scientists at The Scripps Research Institute (TSRI) have discovered the molecular mechanism by which the deadly Ebola virus assembles, providing potential new drug targets.

16 Aug 2013

Experimental vaccine elicits antibodies that can protect against Ebola virus infection

Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.

16 Jan 2013

Antibody-based therapies successfully protect monkeys from deadly Ebola and Marburg viruses

Army scientists have demonstrated, for the first time, that antibody-based therapies can successfully protect monkeys from the deadly Ebola and Marburg viruses. In addition, the animals were fully protected even when treatment was administered two days post-infection, an accomplishment unmatched by any experimental therapy for these viruses to date.

14 Mar 2012

Scientists identify critical protein responsible for Ebola virus infection

In separate papers published online in Nature, two research teams report identifying a critical protein that Ebola virus exploits to cause deadly infections. The protein target is an essential element through which the virus enters living cells to cause disease.

25 Aug 2011

NIH awards grant to Bavarian to advance early research in filoviruses

Bavarian Nordic A/S announced today that the company has received funding from the U.S. National Institutes of Health (NIH) to advance its early research in filoviruses (Ebola and Marburg virus).

14 Oct 2010

New antisense drugs may help treat accidental infections: Study

New studies show that treatments targeting specific viral genes protected monkeys infected with deadly Ebola or Marburg viruses. Furthermore, the animals were protected even when therapeutics were administered one hour after exposure-suggesting the approach holds promise for treating accidental infections in laboratory or hospital settings.

23 Aug 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

Update on suspected Acute Haemorrhagic Fever in Republic of the Congo

Blood samples taken from one of the suspected cases in Sangha Region, Republic of Congo, tested negative for several viral haemorrhagic fevers (Ebola, Marburg, CCHF, Arenavirus).

5 Jul 2010

Virus related to hepatitis C discovered in Asian bats

Viral hepatitis affects more than 500 million people worldwide and is a cause of liver failure and liver cancer. While vaccines are available for hepatitis A and B, this is not the case for hepatitis C, which affects as much as two percent of the population in the U.S. Scientists today are reporting discovery of a virus related to hepatitis C in Asian bats, which may provide insights into the origins of the hepatitis C virus and into the mechanisms by which infectious diseases move from other species to humans.

2 Jul 2010

Experimental vaccine for Marburg hemorrhagic fever prevention shows promise for accidental exposures

An experimental vaccine developed to prevent outbreaks of Marburg hemorrhagic fever continues to show promise in monkeys as an emergency treatment for accidental exposures to the virus that causes the disease. There is no licensed treatment for Marburg infection, which has a high fatality rate.

17 Jun 2010

DFG approves establishment of twelve new CRCs

The Deutsche Forschungsgemeinschaft has approved the establishment of twelve new Collaborative Research Centres beginning 1 July 2010. This was decided by the responsible Grants Committee at its spring meeting in Bonn. The new CRCs will initially be funded for four years with a total of 112 million euros (including a 20% programme allowance for indirect project costs).

29 May 2010

Third International Epilepsy Colloquium to be hosted in Cleveland

About 200 epilepsy specialists, neurosurgeons and pediatric neurologists from around the nation and the world are registered to attend the Third International Epilepsy Colloquium in Cleveland from May 19 to 22. The conference is sponsored by the Neurological Institute at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine.

19 May 2010

Inflammation enzyme regulates production of brown fat tissue

Love handles, muffin tops and stomach tires - white fat tissue forms the typical curves in the notorious problem areas to store energy. Exactly the opposite happens in brown fat tissue: Instead of being stored, energy gets transformed into heat. To the dismay of many people, adults have only small amounts of this energy burner. By contrast, babies and animals in hibernation have lots of it in their bodies where it serves for heat regulation.

7 May 2010

On-going phase II trial of octagam in AD to be discussed at ICAD 2010

The on-going phase II trial on Octapharma's 10% intravenous immunoglobulin octagam®10% will be a topic at the up-coming International Conference on Alzheimer's Disease to take place in Honolulu, Hawaii from July 10 to 15.

20 Apr 2010